We report the x-ray structures of several bisphosphonate inhibitors of geranylgeranyl diphosphate synthase, a target for anti-cancer drugs. Bisphosphonates containing unbranched sidechains bind to either the farnesyl diphosphate (FPP) substrate site, the geranylgeranyl diphosphate (GGPP) product site, and in one case, both sites, with the bisphosphonate moiety interacting with 3 Mg 2+ that occupy the same position as found in FPP synthase. However, each of three "V-shaped" bisphosphonates binds to both the FPP and GGPP sites. Using the Glide program, we reproduced the binding modes of 10 bisphosphonates with an RMS error of 1.3Å. Activities of the bisphosphonates in GGPPS inhibition were predicted with an overall error of 2x, using a comparative molecular similarity analysis, based on a docked-structure alignment. These results show that some GGPPS inhibitors can occupy both substrate and product site, and that binding modes as well as activity can be accurately predicted, facilitating the further development of GGPPS inhibitors as anti-cancer agents.
Introduction
Geranylgeranyl diphosphate synthase (GGPPS, EC 2.5.1.30) catalyzes the formation of geranylgeranyl diphosphate (1) from one molecule of farnesyl diphosphate (2) and one molecule of isopentenyl diphosphate (3) 1 :
The GGPP product is used in the biosynthesis of many natural products, such as taxanes and gibberellins, and is also used to prenylate proteins such as Rho, Rap and Rac, involved in cell signaling pathways 2, 3, Figure 1 . It can be further elongated by some polyprenyl synthases 4 to produce the long chain isoprenoids used in quinone biosynthesis, and in plants and some bacteria, two GGPP molecules can condense to form phytoene, the precursor for many carotenoids 5 . GGPPS is inhibited by a variety of bisphosphonates 6-9 , and is of current interest in the context of the development of anti-cancer drugs 7, 8 which function by inhibiting protein prenylation, cell signaling and cell survival pathways, Figure 1 .
In earlier work 6 , we found that n-alkyl bisphosphonates such as 4:
had quite potent activity against GGPPS, and more recently, Weimer et al. have reported 7, 8 that novel diprenyl methylenebisphosphonates, such as digeranyl methylene bisphosphonate (5) , have potent activity against GGPPS, as well as against a K562 tumor cell line, but the structures of neither the n-alkyl nor any dialkenyl bisphosphonate inhibitor-GGPPS complexes have been reported. The structure of human GGPPS is now known, however, with in recent work, Kavanagh et al. 10 finding the presence of the "isoprene fold" found in other prenyl synthases, such as farnesyl diphosphate synthase (FPPS, EC 2.5.1.10) 11-14 . These workers also showed 10 that the GGPP product bound to a central "inhibitor" binding site, and in more recent work 9 , we have found that other GGPPS inhibitors such as 6 (which is too large to inhibit FPPS) also bind to this site, and are potent inhibitors of GGPPS activity. We also found that GGPPS substrates and diphosphate and bisphosphonate inhibitors can bind in four distinct ways to GGPPS, with their polar (diphosphate, bisphosphonate) groups binding to either the FPP or IPP diphosphate binding sites, and their more hydrophobic fragments binding to the (human) GGPP (inhibitor) site, or to the FPP (substrate) site 9 . Here, we report the first structures of a series of n-alkyl and dialkenyl bisphosphonates bound to GGPPS. We also show that the binding modes seen crystallographically can be well predicted computationally, facilitating the development of quantitative structure-activity models. Given the widespread use of bisphosphonates in treating bone resorption diseases and the current interest in them as anti-cancer agents 15-17 , these results are of broad general interest since they lay the foundation for the further development of, in particular, the novel disubstituted bisphosphonates.
mode, seen only so far with 8, the IPP polar site is occupied by the polar bisphosphonate, and the large hydrophobic sidechain site resides in the hydrophobic GGPP (human) site, Figure  S1C . And in the fourth binding mode, seen so far only with GGPP in the Saccharomyces cerevisae (yeast) GGPPS structure, the polar diphosphate of GGPP occupies the polar IPP site, while the hydrophobic sidechain occupies the FPP (substrate) hydrophobic sidechain site, Figure S1D . These observations clearly pose a challenge for structure based inhibitor design, since it is by no means clear how a given, novel inhibitor, might bind. We elected, therefore, to investigate the structures of the following series of inhibitors:
which, when combined with previous structures, 9 might provide a data base with which to test the results of computational docking calculations. If successful, it might then be possible to use docked structures of a much larger range of inhibitors (whose crystallographic structures are not known), to develop quantitative structure activity relationships using, in particular, the comparative molecular similarity index analysis (CoMSIA) method 18 . For the simpler bisphosphonates, it seemed possible that several of the four binding poses seen previously ( Figure S1 ) might be possible, while for the branched chain species (5, 12, 13) , it seemed likely that more than one site might be needed, in order to accommodate these "V-shaped" molecules.
To investigate the numerous possibilities for n-alkyl bisphosphonate binding, we first determined the structure of 4 bound to GGPPS, obtaining two structures. In the first, we find that 4 (yellow) binds to the FPP site (FPP-FPP) (Figures 2A,B ; PDB File 2z4x). The bisphosphonate fragment coordinates to three Mg 2+ (yellow), Figure 2B , which in turn are coordinated to the DDXXD repeats ( Figure 2A ). The C8 side-chain is closely aligned to the thiolo-farnesyl diphosphate (FsPP) side-chain seen in the FsPP-IPP-GGPPS structure (PDB File 2e8t) and, as can be seen in the superposition shown in Figure 2C , the three Mg 2+ are closely aligned to the three Mg 2+ seen in many FPPS structures [11] [12] [13] [14] 19 , with a ~0.32 Å RMSD between the Mg 2+ positions in the GGPPS (PDB File 2z4x) and FPPS/IPP/zoledronate (PDB File 2f8z) structures. Essentially the same binding pattern is seen with the longer chain species 11 , Figure S2 . These structures present the first observation of 3 Mg 2+ bound to GGPPS and, as can be seen in Figure 2C , the similarity in metal binding in GGPPS and FPPS is clear. So, at least for medium-length side-chains (about the length of GPP), the FPP-binding site is an important target for bisphosphonates, as is binding to Mg 2+ . Surprisingly, however, in a second structure of 4, we find evidence for two binding sites for 4, in chain A (1 in chain B). In this structure (PDB File 2z4y, chain 1A), Figure 2D , one inhibitor molecule binds to the FPP site while a second binds to the IPP-GGPP product/inhibitor site, the same binding pattern as seen previously with 8 9 . There is, therefore, some variability in how bisphosphonates bind to GGPPS and indeed, this variability is also seen with binding of the GGPP product where in earlier work 9 , we found GGPP bound to the IPP/FPP site ( Figure S1D ), in contrast to the FPP/GGPP binding mode seen with the human enzyme 10 . However, in a new structure (PBD 2z4v) we find the same binding pattern as seen in human GGPPS ( Figure 2E , pink), due presumably to the slight changes in crystallization conditions (higher [Mg 2+ ]) employed in the current investigation. Ligand interaction diagrams for all of the new structures are shown in Figures S3. We find that that bisphosphonate groups of both 4 (P2 1 ) and 11 coordinate to three Mg 2+ , which in turn are coordinated to the DDXXD repeats. The bisphosphonate backbones form H bonds with Arg84, Lys169 and Lys233. In a second structure of 4, 4 can bind to two sites; one in the FPP site, interacting with the side chains of Arg84, Lys169, Gln206 and Lys233, the other one in the GGPP product site, interacting with Arg39, His68, Arg84 and Arg85. In the case of 10, there is no Mg 2+ observable, and the bisphosphonate backbones interact with the side chains of Asp75, Arg84 and Lys233 via hydrogen bonds.
The wide range of binding modes observed experimentally suggests the possibility that two sites might be occupied by the 1,1-disubstituted bisphosphonates, such as 5,12, which could bind in a "V-shaped" conformation that could easily occupy both the FPP-FPP and FPP-GGPP sites ( Figure S1A,B) or the IPP-GGPP and IPP-FPP sites ( Figure S1C,D) . The former turns out to be the case as can be seen in Figure 3A where we see the location of the two geranyl chains in 5 (plus Mg 2+ ) bound to the GGPPS dimer, illustrating binding to the FPP and GGPP sites. Close-up views of 5,12 and 13 (PDB Files 2z4w, 2z4z and 2z78) superimposed on the FsPP and GGPP ligands in GGPPS (PDB Files 2e8t, 2z4v) are shown in Figures 3B-D (ligand interaction plots are provided in Figures S4A-C) and clearly indicate that each of these "Vshaped" molecules bind to both the FPP and GGPP (substrate, inhibitor) sites. A major difference between the three structures is, however, that the number of Mg 2+ varies, ( Figures  3B-D) . The 2 Mg 2+ (green) that are seen in the 5 structure occupy the same positions as those seen in the 3 Mg 2+ structures (Figures 2B,C), but there are no Mg 2+ seen in the two other structures, which might, however, simply reflect the relatively low pH (~4.8) required for crystallization, making Mg 2+ -binding relatively weak. Data collection and refinement statistics for 5, 12 and 13 bound to GGPPS are shown in Table 4 .
In addition to these structures, we also determined the structures of a shorter (C 6 ) n-alkyl inhibitor (10) as well as that of a potent long chain phosphonium inhibitor (9), bound to GGPPS, Figure S5A ,B. Data collection are refinement statistics are shown in Table S1 in the Supporting Information. We find that the long chain phosphonium bisphosphonate binds to the GGPP inhibitor site while the short chain n-alkyl species binds to the FPP site, as illustrated in Figures  S5A,B . Electron densities for all structures reported here are shown in Figure S6 .
These results are clearly of interest in the context of deducing structure-activity relationships for GGPPS inhibition, not least since there are clearly several different types of binding that might be anticipated for a given compound, which would be expected to complicate the use of purely ligand-based predictions of activity. We thus next consider how these crystallographic results might be used to guide QSAR investigations.
Bisphosphonate Activities and QSAR
We investigated the activities in GGPPS inhibition of the 60 bisphosphonates (plus 1 phosphosulfonate, 61) shown in Figure 4 . The most potent inhibitors (Table 1) all contained long alkyl chains, with short chain species -conventional bisphosphonates such as pamidronate (62), risedronate (64) and alendronate (65) having essentially no activity (> 100 μM). Two phosphonate groups were essential for activity (e.g. 8, IC 50 = 4 μM; the phosphonosulfonate analog 61 had no detectable activity), but unlike FPPS inhibition, a cationic center was not essential for good activity, e.g. 15, IC 50 = 0.3 μM; 19, IC 50 = 0.6 μM. Likewise, the neutral sidechain species 5 had an IC 50 = 1 μM. So, the cationic species are not acting as carbocationic transition state/reactive intermediate analogs, as they do in FPPS inhibition 20 .
In order to interpret the activity results (Table 1) , it seemed likely that it would be necessary to deduce the most probable binding site for each inhibitor, since the activity of a given compound would be expected to depend on which site it occupied. To do this, we first investigated the docking poses (using Glide 21 ) of 12 inhibitors whose crystallographic structures were known, in order to validate this approach. Using a superposition of 12 bisphosphonate-GGPPS complexes ( Figure 5A) , we selected five different structures to serve as target receptors. They contained zero, one, two (2 structures) or all three Mg 2+ ions, and had a variety of protein sidechain (Leu138, Arg39 and Arg85) conformations ( Figure 5B and Table S2 ). Of the five structures, the GGPPS containing compound 8 yielded the best docking results (Table S2) , most likely because it had two large bound ligands, with the protein (PDB File: 2e93) sidechain orientations ( Figure 5B , cyan) permitting binding to many different inhibitors.
Twelve inhibitors whose active site conformations were known crystallographically were then docked into each target receptor in a cross docking approach, specifying no constraints, using Glide 21 . The results obtained were then compared with the known crystallographic results, with the GGPPS 8 "Mg 2+ BC " structure ( Figure 5B , PDB File: 2e93) providing the best overall results (Table S2 ) Using this structure we found, on average, a 1.3 Å RMSD between the xray and docked poses, with the correct binding site predicted in all cases. We observed slightly worse results for the other receptor containing 2 Mg 2+ , and very poor results for each of the other receptors (full details shown in Supporting Tables S2 and S3 ). Interestingly, the GGPPS 8 structure (which gave the best docking results) contains two bulky bisphosphonates, and can presumably accommodate ligands having diverse structures.
We next docked 51 additional GGPPS inhibitors, having a large range of activity (~0.1-150 μM, Figure 5 and Table 1 ) to the GGPPS 8 structure. A surface representation of all x-ray and predicted binding poses is presented in Figure 6A , and clearly shows the presence of two different binding sites. In all cases, the lowest energy poses of each inhibitor were those that might be deduced based on chemical similarity to known inhibitors. However, despite the good predicted binding poses, the docking score (G Score in Glide) was only weakly correlated with GGPPS inhibition (r 2 = 0.3, Figure 6B ). A possible explanation for this is that although the calculations were performed using the highest level of accuracy available in Glide 4.5 21 (extraprecision mode), the receptor is still treated rigidly, 22 so the accuracy of the scoring function might be compromised. To improve the docking score, we next investigated the use of the linear interaction approximation (LIE) 23 method in the Liaison 24 program. This performs molecular mechanics simulations on the bound and free states of the enzyme-ligand complex using a continuum-solvent model, 24 and takes into account receptor flexibility. However, improvements were small: r 2 =0.4, Figure 6C . Finally, we constructed a re-parameterized energy function, based on the experimentally determined activities, computed energies and the lipophilicity molecular descriptor, SlogP 25 . This resulted in a further improvement with experiment: r 2 = 0.6, q 2 = 0.6, F = 85, Figure 6D , Table 1 , and using a training and test set approach, we found that IC 50 values could be predicted within a factor of 3x (over a range of 4000x in activity). Full output results are shown in Table S4 . So, while promising, these results are clearly worse than those we have obtained previously using CoMSIA or CoMFA (comparative molecular field analysis) methods for bisphosphonate inhibition of a variety of enzymes in which only a single site is occupied 16, 26, 27 . We thus next investigated the use of CoMSIA methods to predict activity. Structurally similar compounds were aligned to their closest x-ray structure, followed by a flexible common feature superposition, as described previously 16 . The alignment and fields, Figure 7A -C, resulted in a q 2 = 0.59, r 2 = 0.8, F = 73, n = 61, Figure 7D . Full results are shown in Tables S5 and S6 . Although these results are quite promising, it seemed logical to see to what extent they might be improved upon by using a receptor-guided alignment 28 based on the Glide docking results discussed above. The CoMSIA fields so obtained are shown in Figure 7E -G and using this receptor-guided alignment found that all three parameters, q 2 , r 2 and F, improved. The q 2 parameter increased from q 2 = 0.6 to q 2 = 0.7; r 2 from 0.8 to 0.9, and F from 73 to 166, Figure  7H , with predictions now within a factor of 2x (over a 4000x range in activity). Full results are shown in Tables 2 and S7 . Also of importance, the receptor-guided alignment could be generated rapidly, and in a uniform manner, for all compounds. Despite the slight differences in the predictivity of the models obtained from the two alignments, the CoMSIA fields produced are very similar, with a steric-favorable region (green) coincident with the end of the FPP-GGPP sites in the protein, consistent with the observation that long alkyl species typically provide maximum inhibitory effects. Additionally, the hydrophobic-favorable CoMSIA fields (orange) are very prominent, especially in the receptor-guided alignment ( Figure 7G ), consistent again with the high potency of the long alkyl (and dialkyl) bisphosphonates in GGPPS inhibition.
Conclusions
The results we have obtained above are of interest since they show how n-alkyl and dialkenyl bisphosphonates bind to, and inhibit, the GGPPS enzyme. All three n-alkyl bisphosphonates bind to the FPP site. Surprisingly, however, in one case we find that the GGPP site is also occupied, and in two structures (PDB Files 2z4x and 2z52), of the 24 GGPPS structures now investigated, we see for the first time the presence of three Mg 2+ , located in essentially the same position as found in many FPPS-bisphosphonate structures 10-13 . The dialkenyl bisphosphonates investigated both bind with their polar groups in the FPP/GGPP polar binding site, but one side-chain occupies the FPP hydrophobic site, while the second occupies the GGPP inhibitor site, basically as seen with the doubly-occupied n-alkyl bisphosphonate structure. A similar arrangement is seen with another, biphenyl-containing, "V-shaped" inhibitor. A computational investigation produced models with varying degrees of predictive utility. Docking scores performed worst (r 2 0.3), a linear interaction approximation (LIE) method had moderate predictivity (q 2 0.6, r 2 0.6), while a receptor-guided CoMSIA alignment method performed best overall (q 2 0.7, r 2 0.9). Given the selective GGPPS inhibition of the dialkenyl bisphosphonates, and their activity in cell-based assays, the availability of these new crystal structures is of broad general interest in the context of the development of potent and specific tumor cell growth inhibitors, where GGPPS inhibition offers a potentially interesting alternative to conventional FPPS-based cell growth inhibition by bisphosphonates, not least because such hydrophobic species are expected to bind only weakly to bone mineral 29 .
Experimental Section Chemicals
All reagents used were purchased from Aldrich (Milwaukee, WI). The purities of all compounds were routinely monitored by using 1 H and 31 P NMR spectroscopy at 400 or 500 MHz on Varian (Palo Alto, CA) Unity spectrometers using, in some instances, absolute spincount quantitative analyses. The elemental analysis results for all new compounds are provided in the Supporting Information (Table S8) 2-(5-Decyloxypyridin-3-yl)ethylidene-1,1-bisphosphonic acid (40) was prepared using the following scheme:
To a suspension of NaH (480 mg, 60 %, 12 mmol) in THF at 0 °C was added tetraethyl methylene bisphosphonate (2.88 g, 10 mmol). The mixture was allowed to stir at room temperature for 30 minutes. Then 3-decyloxy-5-chloromethyl-pyridine (2.83 g, 10 mmol) followed by NaI (12 mmol) were added, and the reaction mixture stirred for 2 hours at 80 °C. The mixture was quenched with saturated aq. NH 4 Cl. After extraction with ether, the pyridinebisphosphonate was purified by flash chromatography as a colorless oil (50 % yield 
3-(2, 2-bisphosphono-ethyl)-5-ethoxy-1-methyl-pyridinium iodide (14)-The
pyridine-bisphosphonate 66 (1 mmol) was treated with MeI (5 mmol) in ether (5 mL) overnight. Upon removal of the solvent, the residue was hydrolyzed in refluxing concentrated HCl (37 %). After removal of the volatile solvent, the concentrated residue was washed with hexane, ether and then acetone to afford 14 as a grey powder. 1 Octyl-1-(3-decyloxybenzyl)-1, 1-bisphosphonic acid (BPH-804) was made using the following scheme:
1-
To a suspension of NaH (480 mg, 60 %, 12 mmol) in THF at 0 °C was added tetraethyl methylenebisphosphonate (2.88 g, 10 mmol). The mixture was allowed to stir at room temperature for 30 minutes. Then, 1-bromo-2-octane (1.9 g, 10 mmol) was added, dropwise. After 6 hrs, more NaH (480 mg, 60%, 12 mmol) was added, followed by 1-bromoethyl-3-decyloxy-benzene (3.59g, 11 mmol). The mixture was stirred overnight and quenched with aqueous NH 4 1-(2-octenyl)ethylidene-1,1-bisphosphonic acid (12) was made using the following scheme:
1,
To a suspension of NaH (1 g, 60 %, 25 mmol) in THF (15 mL) at 0 °C was added tetraethyl methylenebisphosphonate (2.88 g, 10 mmol) and the mixture was allowed to stir at room temperature for 30 minutes. 1-Bromo-oct-2-enyl (5.7g, 30 mmol) was then added, dropwise, the mixture stirred overnight, then quenched with aqueous NH 4 3-Aminophenyl boronic acid (6 mmol), methyl 3-bromophenyl acetate (5 mmol), Na 2 CO 3 (15 mmol), Pd(PPh 3 ) 4 (50 mg) in toluene (20 mL), H 2 O (3 mL) and ethanol (3 mL) were heated at 110 °C under N 2 overnight. After extraction with diethyl ether, the (3′-amino-biphenyl-3-yl)-acetic acid methyl ester product was purified by column chromatography (56% yield). (3′-Amino-biphenyl-3-yl)-acetic acid methyl ester (5 mmol) and 2-naphthalene sulfonyl chloride (5 mmol) were then dissolved in anhydrous CH 2 Cl 2 (10 mL), followed by addition of pyridine (10 mmol), dropwise. After washing with HCl (3N, 3 mL) , the sulfonamide was isolated after chromatography as a syrup (78%). The ester (1 mmol) was then hydrolyzed with 3 N NaOH (1 mL) in methanol (5 mL) at room temperature for 1 h. After acidification with 2 N HCl, methanol was removed, and the resulting carboxylic acid filtered, then washed with water. The dried acid was dissolved in benzene (5 mL) and oxalyl chloride (2 mmol) added, followed by one drop of DMF. The reaction mixture was then stirred for 1 h. Upon removal of solvent, the crude acid chloride so obtained was dissolved in dry THF (5 mL) and P(OTMS) 3 (2 mmol) was added. After 3 h at room temperature, solvent was removed, methanol-H 2 O (2 mL, 1:1) added, and the mixture stirred for 30 min. Concentrated aqueous NaOH was then added to precipitate the target compound, which was washed thoroughly with methanol, then ether, and dried to afford the bisphosphonic acid as its sodium salt. Hydroxy-2-(3-decyloxyphenyl)ethylidene-1,1-bisphosphonic acid. (19)-19 was prepared from (3-decyloxy-phenyl)-acetic acid methyl ester, by hydrolysis with NaOH and bisphosphorylation with P(OTMS) 3 , as described for 6. Anal. (C 18 H 31 NaO 8 P 2 ·0.5H 2 O) C, H, N. 1 Protein Expression and Purification-Yeast and human GGPPS were expressed and purified as described previously 6, 30 . The molecular weights of the purified enzymes were verified by mass spectrometry, and purities (>95%) determined by SDS/PAGE.
1-
Crystallization and data collection for GGPPS complexes-Native GGPPS crystals for soaking were obtained by using the hanging drop method (Hampton Research; Laguna Niguel, CA) by mixing 2 μL of a GGPPS solution (5-10 mg/mL GGPPS in 25 mM Tris-HCl, pH 7.5 and 150 mM NaCl) with 2 μL of mother liquor (0.08 M CH 3 COONa, pH 4.6, 16% PEG 4000, 6-10% glycerol, and 6-10% 1,2-propanediol), and equilibrating with 500 μL of the mother liquor. Crystals grew to 0.5 × 0.2 × 0.2 mm in 7 days, at room temperature, then were soaked in cryoprotectant solution containing 2.5 mM MgCl 2 , 2.5 mM GGPP product or bisphosphonate (4, 5, 10, 11, 12) , 0.08 M CH 3 COONa, pH 4.6, 20% PEG 4000, 10% glycerol, and 10% 1,2-propanediol, for 3-12 h.
For preparing GGPPS-Mg-4 (P2 1 ) crystals, 2 μL of GGPPS-substrate solution (5-10 mg/ml GGPPS, 2.5 mM Tris-HCl, 150 mM NaCl, 2.5 mM MgCl 2 , 2.5 mM BPH252, pH 7.5) were mixed with 2 μL mother liquor (0.08 M CH 3 COONa, pH 4.6, 12-16% PEG 4000, 8-10% glycerol, and 10% 1,2-propanediol) then were equilibrated with 500 μL mother liquor by using the hanging drop method, at room temperature. Crystals appeared in 5-7 days, and grew to 0.5 × 0.5 × 0.1 mm, then were soaked with cryoprotectant (containing 2.5 mM MgCl 2 , 0.08 M CH 3 COONa, pH 4.6, 20% PEG 4000, 10% glycerol, and 10% 1,2-propanediol) for 3 s, then frozen in liquid nitrogen. GGPPS-Mg-4 (P2 1 ) was the only structure obtained by cocrystallization. All other crystals were obtained by soaking the native crystals with the bisphosphonates (using the same soaking method as described above).
X-ray diffraction data were collected at beamline BL13B1 of the National Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan) and Taiwan Contract BL12B2 station at Spring-8 (Hyogo, Japan). Diffraction data were processed and scaled by using the program HKL2000 31 . GGPPS-Mg-GGPP and eight GGPPS-bisphosphonate crystals belonged to the P2 1 2 1 2 1 space group and had typical unit cell parameters of a = 46-48 Å, b = 116-119 Å, and c = 126-130 Å. The monoclinic crystal (GGPPS-Mg-BPH252-p21) had unit cell parameters of a = 82 Å, b = 48 Å, c = 92 Å and b = 111°. Each asymmetric unit contained a dimeric GGPPS molecule. Prior to use in structural refinements, 5% randomly selected reflections were set aside for calculating R free as a quality monitor 32 .
Structure determination and refinement-The structures of the GGPPS-complexes were determined by using the native GGPPS structure (2DH4) solved previously, since the new crystals were isomorphous. For GGPPS, the 2Fo-Fc difference Fourier map showed clear electron densities for most amino acid residues, including those in the substrate binding site (s), but several loops and the C-terminal segments were disordered. Most product and bisphosphonate electron densities were obvious. Subsequent refinement with incorporation of the cofactors and water molecules at a 1.0σ map level yielded R and R free values of 0.17-0.21 and 0.21-0.26, respectively, at 1.86-2.45 Å resolution. Statistics for the final models are listed in Tables 3,4 and S1. All manual modifications of the models were performed on an SGI Fuel (Silicon Graphics, Mountain View, CA) computer using the XtalView 33 program. Structure refinements, which included maximal likelihood and simulated-annealing protocols, were carried out by using CNS 34 . The PyMol (http://pymol.sourceforge.net/) program was used in creating figures.
GGPPS inhibition
GGPPS inhibitor screening was carried out basically as described previously 6, 9 .
Molecular docking
Docking calculations were performed for all crystallographically determined protein-ligand complexes using a cross-docking approach to a series of GGPPS-bisphosphonate complex structures (5, PDB: 2z4w; 8, PDB: 2e93; 9, PDB: 2z71; 10, PDB: 2z5011, PDB: 2z52). The target proteins were prepared using the protein preparation wizard in Maestro 8.0 35 . Hydrogen atoms were added and a +2 charge assigned to Mg ions present in the active site. In one case, Mg ions were modeled into the active site by initially placing them into locations observed in other GGPPS-bisphosphonate complexes. A full energy minimization in MacroModel 36 was then run on the entire protein to optimize the geometry using default protein parameters. For all other structures, hydrogen bonds were optimized to the default value. A receptor grid large enough to encompass all crystallographically observed binding sites was then generated from the prepared target protein. Constraints for the Mg 2+ ions were created, but not actually used subsequently. Water and hetero-atoms > 5Å from the active site region were removed. Geometry optimized ligands were prepared using LigPrep 37 , specifying a target pH 7.0 with tautomer and stereoisomer generation. For the docking calculations, standard-precision (SP) was specified for preliminary calculations, and the extra-precision (XP) mode specified for the final calculations. Crystallographically determined ligand poses from each structure were then compared with the top 5 poses obtained from Glide; the RMS errors are reported in the Text and in Tables S2 and S3 . Docking poses were exported to Sybyl 38 for CoMSIA analysis and also into Liason, 24 for scoring function parameterization.
Docking Scoring Function Parameterization
Predicted docked poses of all ligands investigated (generated above) were imported into Liaison 24 for molecular-mechanics energy calculations. Default options were specified including a minimization sampling method using a truncated Newton algorithm. Ensemble averages of van der Waals, electrostatic and cavity (solvent exposed ligand surface area) energies were computed for the ligand-bound and ligand-free states using an implicit solvation model. The computed energies for each inhibitor complex and SlogP 25 (computed in MOE) were then imported into Strike, 39 where partial-least-squares (PLS) and multiple linear regression (MLR) methods were applied, to construct a linear equation representing binding affinity. The optimal number of components was automatically selected, and outliers identified. All molecules were used to construct an initial training set, then five test sets were selected at random from the dataset. Each test set compound was removed from the subsequent training set, with binding affinities being predicted by using the constructed linear equation. Coefficients for each energy term, fitting statistics and predictions were reported, and are shown in Tables S2 and S5 .
Receptor-guided alignment
Based on the best prediction of crystallographic binding poses among all complexes, the target protein receptor (GGPPS-8, PDB: 2e93) was selected as the target receptor, and prepared as described above using the protein preparation wizard in Maestro 8.0 35 . Inhibitor structures were prepared as described above using LigPrep 37 . The prepared receptor grid and inhibitors were then used in a Glide 4.5 21 docking calculation, specifying extra-precision (XP).
Flexible Common Feature Alignment
Inhibitor structures were imported into MOE 2006.08, 40 where three-dimensional structures were generated using a course energy minimization protocol and the MMFF94 force field 41 . An alignment was constructed by using crystal structures of bound inhibitors as a template.
Additional inhibitors were added in a sequential manner to the template structures, employing the flexible alignment protocol implemented in MOE. Default gradient, RMSD and similarity terms were used, with the refine option selected. The final alignment was then exported to Sybyl for CoMSIA analysis.
CoMSIA Analysis
The aligned structures were exported from Maestro into Sybyl 7.3 38 and CoMSIA 18 fields computed for the aligned structures, using default grid spacing and probe atom types. Partialleast-square (PLS) regression was used to assign coefficients to grid points based on the experimentally determined GGPPS pIC 50 values (where pIC 50 = −log 10 (IC 50 , [M] ). The SAMPLS 42 method was used to determine the optimum number of components in the regression models. The final model was selected based on cross-validated r 2 (q 2 ), r 2 , error and number of components, such that a statistically robust model could be generated with a minimum number of components. Test-set calculations were performed using 5 iterations of a leave 20% out approach. We used the progressive scrambling routine in Sybyl 7.3 to assess the stability of the model, by applying random activity value perturbations to structurally similar molecules within the dataset. Predictive ability, as measured by change in q 2 with respect to perturbed dependent variables, should remain constant through the series of perturbations, with the optimum value of 1, for stable models.
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